Clinical trials have shown that Xtandi can significantly extend progression-free survival and overall survival in men with mCRPC and nmCRPC. It has been proven to delay the need for chemotherapy and reduce the risk of cancer spreading to other parts of the body. These benefits make Xtandi a valuable treatment option for men with advanced prostate cancer.
